

Medical Oncology

Outpatient Clinical Drug Trials Solution for 1199SEIU Benefit Funds



HITRUST
CSF Certified

 Quality Improvement Organizations
Sharing Knowledge. Improving Health Care.
CENTERS FOR MEDICARE & MEDICAID SERVICES



Empowering
the Improvement
of Care

Outpatient Oncology Clinical Trial Management Overview

Effective 1/1/2023, 1199SEIU Benefit Funds Medical Oncology prior authorization program will begin accepting prior authorization requests for pediatric and adult Medical Oncology outpatient clinical drug trials through eviCore healthcare.

- Prior approval requests will still be initiated through www.eviCore.com or by phoning eviCore at 888-910-1199.
- Outpatient medical oncology clinical trial prior authorization will be required for all Benefit Fund active members, and will include pediatric and adult patients.
- Outpatient medical oncology clinical trials beginning prior to 1/1/2023, utilization review will continue to be managed by Benefit Funds.
- Beginning on 1/1/2023, patients enrolled in an outpatient medical oncology clinical trial will be required to obtain a prior authorization through eviCore.
- eviCore will review treatment regimens to ensure they meet with coverage policy guidelines. If the prior authorization does not adhere to our medical oncology coverage policy, the request will be denied. A denial notification will be sent out, containing the clinical appeal process.

Outpatient Oncology Clinical Trial Management Overview

Effective 1/1/2023, 1199SEIU Benefit Funds Medical Oncology prior authorization program will begin accepting prior authorization requests for pediatric and adult Medical Oncology outpatient clinical drug trials through eviCore healthcare.

- Inpatient and ER Patients do not require prior authorizations through eviCore. For Inpatient prior authorization you will continue to contact Care Allies at (800)227-9360
- eviCore will review the trial protocol to ensure it meets coverage policy guidelines
- If the trial contains Standard of Care drugs that fall under the coverage policy, an authorization will be issued that covers those drugs and identifies the trial drugs that are not covered (Experimental and Investigational) and must be covered by the trial Sponsor
- If the outpatient clinical trial period is greater than the eviCore Standard of Care drug authorization, then the provider should contact eviiCore to extend the authorization
- If the patient disenrolls from the trial or a trial is discontinued, the provider should contact eviCore regarding alternate treatment authorizations

Oncology Clinical Trial Match

- eviCore will include the new **Clinical Trial Match** service. This is an informational service embedded in the existing prior authorization process that is designed to help raise awareness of possible trial options for your patients.
- During a standard prior authorization request eviCore will search the NCI trial database using clinical information gathered during the request to surface potential clinical trial matches. You may elect to have this list sent to you for further review.
- Sharing the clinical trial information with you, will not delay the prior authorization review or determination.

Outpatient Oncology Clinical Trial Management Information

The oncology medications coverage policy is available on the eviCore website (www.evicore.com)


<https://www.evicore.com/provider/clinical-guidelines-details?solution=medical%20oncology&hPlan=1199SEIU>

Medical oncology outpatient clinical drug trial educational material will be available on the eviCore 1199SEIU Funds resource page.

<https://www.evicore.com/resources/healthplan/1199seiu-funds>

For additional questions, you may contact: clientservices@evicore.com

Select Program



The screenshot shows the eviCore healthcare website interface. At the top left is the eviCore healthcare logo. A dark blue navigation bar contains the following links: Home, Authorization Lookup, Med Solutions Portal, CareCore National Portal, and Help / Contact Us. In the top right corner, there is a user login link: [Log Off \(AMYINTQ\)](#).

The main content area is titled "Request an Authorization". Below the title, it says "To begin, please select a program below:" followed by a list of radio button options:

- Durable Medical Equipment(DME)
- Gastroenterology
- Lab Management Program
- Medical Oncology Pathways
- Musculoskeletal Management
- Radiation Therapy Management Program (RTMP)
- Radiology and Cardiology
- Sleep Management
- Specialty Drugs

In the center of the page, there is a "Loading..." indicator with a progress bar below it. At the bottom left, there is a link: [Click here for help](#) with a mouse cursor icon pointing to it.

Select the Program for your certification.

Creating the Request

The screenshot displays the eviCore healthcare web application interface. At the top left is the eviCore healthcare logo. A navigation bar contains links for Home, Authorization Lookup, Med Solutions Portal, CareCore National Portal, and Help / Contact Us. The main content area is titled 'Requested Service + Diagnosis'. Below this title, it states 'This procedure will be performed on 6/22/2021.' with a 'CHANGE' button. The 'Medical Oncology Pathways' section includes a dropdown menu for selecting a procedure by CPT Code or Description, a link to 'Click here' if the user doesn't see their procedure code, and a note that primary chemotherapy and supportive drugs must be entered as separate requests. The 'Diagnosis' section shows the primary diagnosis code 'C34.02' and description 'Malignant neoplasm of left main bronchus', with a link to 'Change Primary Diagnosis'. Below this is a field for selecting a secondary diagnosis code, with a 'LOOKUP' button. At the bottom are 'BACK' and 'CONTINUE' buttons.

eviCore healthcare

Home Authorization Lookup Med Solutions Portal CareCore National Portal Help / Contact Us

Requested Service + Diagnosis

This procedure will be performed on 6/22/2021. [CHANGE](#)

Medical Oncology Pathways

Select a Procedure by CPT Code[?] or Description[?]

Don't see your procedure code or type of service? [Click here](#)

Primary Chemotherapy and Supportive drugs must be entered as separate requests.

Diagnosis

Primary Diagnosis Code: C34.02
Description: Malignant neoplasm of left main bronchus
[Change Primary Diagnosis](#)

Select a Secondary Diagnosis Code (Lookup by Code or Description)
Secondary diagnosis is optional for Medical Oncology Pathways

[LOOKUP](#)

[BACK](#) [CONTINUE](#)

Oncology Clinical Trial Process

eviCore healthcare
innovative solutions

Home Certification Summary Authorization Lookup Eligibility Lookup **Clinical Certification** Certification Requests In Progress MSM Practitioner Perf. Summary Portal Help / Contact Us

Effective 1/1/2023, 1199SEIU Benefit Funds medical oncology prior authorization program will begin accepting prior authorization requests for pediatric and adult medical oncology outpatient clinical drug trials through eviCore healthcare.

Please select all of the following that apply:

- The patient is participating in a clinical trial that includes cancer treatment drugs
- The requested drug is being used to treat a condition other than cancer
- The treatment will be administered inpatient
- CAR-T Therapy
- This request is for a Stem Cell Transplant conditioning regimen
- None of the above

Submit

If the patient is participating in an outpatient clinical trail, select the appropriate option.
Options other than the clinical trial are not managed by eviCore.

Oncology Clinical Trial Process

Please identify the clinical trial on which the patient is enrolled:

Please enter the Clinical Trial ID using one of the three formats below, including any dash(es):

- *Primary Sponsor ID Example:* 13BT051
- *Secondary NCI ID Example:* NCI-2019-08127
- *ClinicalTrials.gov ID Example:* NCT02323867

Clinical Trial ID:

Submit

Enter Clinical Trial ID using one of the 3 formats indicated.

eviCore will search for the clinical trial ID entered.

Oncology Clinical Trial Process

If you are having trouble locating your clinical trial, you may wish to go to the [NCI website](#) and search for your trial to ensure you have the correct trial ID.

Primary Sponsor ID	Secondary NCI ID	ClinicalTrials.gov ID	Phase	Clinical Trial Title
9881	NCI-2015-01097	NCT02498613	II	A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

- i** Please select an option: *
- Proceed with clinical trial above
 - Repeat your clinical trial search using a different Clinical Trial ID

Submit

Review History

The system will search the clinicaltrial.gov oncology clinical trial database to locate the indicated clinical trial. If found, the information will populate, and you will select the option to proceed with clinical trial.

Lung - Small Cell Lung Cancer

Office

Please select all of the following that apply:

None of the above

Was the patient initially diagnosed with metastatic disease beyond locoregional nodes?

Yes

Oncology Clinical Trial Process

If you are having trouble locating your clinical trial, you may wish to go to the [NCI website](#) and search for your trial to ensure you have the correct trial ID.

Primary Sponsor ID	Secondary NCI ID	ClinicalTrials.gov ID	Phase	Clinical Trial Title
--------------------	------------------	-----------------------	-------	----------------------

No clinical trial found for the clinical trial ID entered.

i Please select an option: *

- Repeat your clinical trial search using a different Clinical Trial ID
- This patient is receiving their treatment as part of a clinical trial, but I cannot find it using the search tool. I want to upload the clinical trial protocol.

Submit

If no clinical trial id is entered, or an incorrect id is entered, an option will be offered to repeat the clinical trial search.

Or

An option to upload the clinical trial protocol can be selected.

Oncology Clinical Trial Process

1 Attach a PDF or Word document:
 No file chosen

1 Attach an additional PDF or Word document:
 No file chosen

Review History

1 Indicate the Cancer Type:
 Prostate Cancer
 Other

1 Please select all of the following that apply:
 None of the above
 Office

1 Was the patient initially diagnosed with metastatic disease beyond locoregional nodes?
 Yes

If the option to upload the clinical trial protocol was selected, it can be uploaded in a PDF or Word document.

Oncology Clinical Trial Process

Clinical Certification

Please indicate the standard of care primary treatment drugs that this patient will receive as part of this clinical trial. The list of supportive drugs will follow.

Drug List:

	Add all	2 items selected	Remove all
5FU (5-Fluorouracil)	+	5-Fluorouracil (Adrucil, 5FU)	-
Abemaciclib - oral (Verzenio)	+	Abiraterone Acetate -Yonsa - oral	-
Abiraterone Acetate - Zytiga - oral (Zytiga)	+		
Abiraterone Acetate -Yonsa - oral (Yonsa)	+		
Abraxane (Paclitaxel (albumin-bound))	+		
Acalabrutinib - oral (Calquence)	+		
Actemra (Tocilizumab)	+		
Actimmune (Interferon, gamma-1b)	+		
Adcetris (Brentuximab Vedotin)	+		
Ado-Trastuzumab Emtansine (Kadcyla)	+		
Adriamycin (Doxorubicin HCL)	+		
Adrucil (5-Fluorouracil)	+		
Afatinib - oral (Gilotrif)	+		

Submit

Oncology Clinical Trial Process

Clinical Certification

Please indicate the standard of care supportive drugs that this patient will receive as part of this clinical trial.

Drug List:

	Add all	2 items selected	Remove all
Darbepoetin alfa (Aranesp) ONCE EVERY 2 WEEKS	+	Darbepoetin alfa (Aranesp) ONCE EVERY 2 WEEKS	-
Darbepoetin alfa (Aranesp) ONCE EVERY 3 WEEKS	+	Epoetin alfa (Epogen, Procit) WEEKLY	-
Darbepoetin alfa (Aranesp) WEEKLY FIXED DOSE	+		
Darbepoetin alfa (Aranesp) WEEKLY WEIGHT BASED DOSE	+		
Denosumab (Prolia)	+		
Denosumab (Xgeva) MONTHLY	+		
Denosumab (Xgeva) MONTHLY and DAY 8, 15	+		
Epoetin alfa (Epogen, Procit) 3 TIMES PER WEEK	+		
Epoetin alfa (Epogen, Procit) ONCE EVERY 2 WEEKS	+		
Epoetin alfa (Epogen, Procit) ONCE EVERY 3 WEEKS	+		
Epoetin alfa (Epogen, Procit) WEEKLY	+		
Filgrastim (Neupogen) 300 mcg single use syringe/vial	+		
Filgrastim (Neupogen) 480 mcg single use syringe/vial	+		

Submit

Oncology Clinical Trial Process

Our records indicate that this clinical trial protocol is associated with the following standard of care drugs:

Code	Description
J9265	Paclitaxel (albumin-bound)
J9190	5 - Fluorouracil - topical
J8999	Abiraterone Acetate – oral
J1442	Filgrastim, injection

Our records indicate that this clinical trial protocol is associated with the following investigational drug(s) that are NOT reimbursable by this patient's health plan:

Code	Description
J9271	Keytruda
No Code Available	Investigational Drug

Please select from the following, then click "Submit":

- Proceed with the above
- Modify standard of care drug list (this case will require eviCore Medical Director review)

Submit

If the billing information is available for the clinical trial. A standard of care & investigational drugs list will populate.

Select from the option to proceed with the populated list or choose to modify the standard of care drug list. If modified, the case will be sent to medical review.

Case Determination Summary

Summary of Your Request

Please review the details of your request below and if everything looks correct click CONTINUE

Your case has been Approved.

Provider Name:

Provider Address:

Contact:

Phone Number:

Fax Number:

Patient Name:

Insurance Carrier:

Patient Id:

Site Name:

Site Address:

Site ID:

Primary Diagnosis Code: C34.2

Secondary Diagnosis Code:

Date of Service: 6/25/2021

Dosage Info:

Description: Malignant neoplasm of middle lobe, bronchus or lung

Description:

I Code	Drug Name	Route	Admin Schedule	Daily max HCPC units	Total HCPC units on auth	Quantity	Refills	Dispensing Source	Site Of Care
J8999	Axitinib - oral	Oral		N/A	N/A	0	N/A	Hospital / Outpatient facility	Outpatient, Home
J9271	Pembrolizumab	Injectable				N/A	N/A	Hospital / Outpatient facility	Outpatient, Home

Authorization Number:

Review Date: 6/23/2021 4:36:24 PM

Expiration Date: 6/25/2022

Status: Your case has been Approved.

CANCEL

PRINT

GO TO PATIENT HISTORY

REQUEST SUPPORTIVES

Thank You!

